Patents by Inventor Keith Selvitelli

Keith Selvitelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ON-COLUMN VIRAL INACTIVATION METHODS
    Publication number: 20230331774
    Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.
    Type: Application
    Filed: January 12, 2023
    Publication date: October 19, 2023
    Inventors: Glen BOLTON, Keith SELVITELLI
  • On-column viral inactivation methods
    Patent number: 11578098
    Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: February 14, 2023
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glen Bolton, Keith Selvitelli
  • ON-COLUMN VIRAL INACTIVATION METHODS
    Publication number: 20200283474
    Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.
    Type: Application
    Filed: February 18, 2020
    Publication date: September 10, 2020
    Inventors: Glen BOLTON, Keith SELVITELLI
  • On-column viral inactivation methods
    Patent number: 10611794
    Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: April 7, 2020
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glen Bolton, Keith Selvitelli
  • On-Column Viral Inactivation Methods
    Publication number: 20160347788
    Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.
    Type: Application
    Filed: September 25, 2014
    Publication date: December 1, 2016
    Inventors: GLEN BOLTON, Keith SELVITELLI
  • ARGININE INACTIVATION OF VIRUSES
    Publication number: 20160010063
    Abstract: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH˜7) or near neutral (˜pH 6 to ˜pH 8) environment.
    Type: Application
    Filed: March 16, 2015
    Publication date: January 14, 2016
    Inventors: Keith SELVITELLI, Justin MCCUE
  • Arginine inactivation of viruses
    Patent number: 8980610
    Abstract: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: March 17, 2015
    Assignee: Biogen Idec MA Inc.
    Inventors: Keith Selvitelli, Justin McCue
  • Arginine Inactivation of Viruses
    Publication number: 20120015424
    Abstract: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.
    Type: Application
    Filed: November 20, 2009
    Publication date: January 19, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Keith Selvitelli, Justin McCue